FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KOZLOV HERSH
2. Issuer Name and Ticker or Trading Symbol

vTv Therapeutics Inc. [ VTVT ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

4170 MENDENHALL OAKS PKWY
3. Date of Earliest Transaction (MM/DD/YYYY)

9/13/2019
(Street)

HIGH POINT, NC 27265
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A common stock  9/13/2019    P    5000.00  A $1.65 (1) 5000.00  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The price reported in column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.6473 to $1.6475, inclusive. The reporting person undertakes to provide to vTv Therapeutics Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote to this Form 4.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
KOZLOV HERSH
4170 MENDENHALL OAKS PKWY
HIGH POINT, NC 27265
X



Signatures
/s/ Rudy C. Howard, attorney-in-fact 9/17/2019
**Signature of Reporting Person Date


vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more vTv Therapeutics Charts.
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more vTv Therapeutics Charts.

Vtv Therapeutics Inc. News

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update
Thursday 9 May 2024 (7 days ago) • GlobeNewswire Inc.
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 9 May 2024 (7 days ago) • Edgar (US Regulatory)
Form 8-K - Current report
Thursday 9 May 2024 (7 days ago) • Edgar (US Regulatory)
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
Tuesday 19 March 2024 (2 months ago) • PR Newswire (US)
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Wednesday 13 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 3 - Initial statement of beneficial ownership of securities
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)
Form SC 13D - General statement of acquisition of beneficial ownership
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
Form 8-K - Current report
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
Monday 4 March 2024 (2 months ago) • GlobeNewswire Inc.
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
Friday 1 March 2024 (2 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Wednesday 28 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 424B5 - Prospectus [Rule 424(b)(5)]
Wednesday 28 February 2024 (3 months ago) • Edgar (US Regulatory)